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focusing on medical devices is currently in development, with the clarification of 
CD’s status expected. However, there is a gap between institutional and scientific 
timelines given that scientific research is already going a step further with the high-
throughput DNA sequencing which would need to be rewarded as well.
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Objectives: Introducing ‘Selective reimbursement scheme’ and reviewing what 
kinds of medical services were involved in plan to strengthen the NHI coverage 
for the four major diseases in 2014. MethOds: The MOHW has been reducing 
the patient’s co-payment ratio to 50~ 80% from 100% for non-reimbursed medical 
services that have large demand for the NHI coverage but the cost-effectiveness 
is low since 2014. A medical service for cosmetic purposes is supposed to be non-
reimbursement category. Once a service or product was assigned to selective reim-
bursed category, reimbursement ratios are determined in 50% or 80% based on the 
evaluation criteria which has 3 aspects of ‘Clinical Usefulness’, ‘Cost Effectiveness’, 
‘Social Demand of Reimbursement’. Results: Based on the evaluation criteria for 
‘Selective reimbursement’, total 12 items were assessed and enlisted in selective 
reimbursement category. This plan benefits 842 thousand patients and reduced 
non-reimbursement cost to 577 million(2014) from 1,119 million(2012) related to 
the four major diseases. cOnclusiOns: NHI coverage is extremely focused on 
the four major diseases and this will cause discrimination against other diseases. 
In terms of patients’ aspect, it may be asked whether this plan is effective to give 
patients an advantage enough to feel under 80% co-payment ratio. The decision 
making process and medical devices price appraisal remains to be considered as 
its transparency and rationality.
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Objectives: Our objective was to estimate the impact of availability of new endo-
vascular therapies on treatment volumes for femoropopliteal arterial disease in 
the German health care system. Germany was among the first markets to adopt 
and reimburse new endovascular techniques including drug-coated balloons 
(DCB), drug-eluting stents (DES), and latest atherectomy devices. MethOds: We 
collected therapy-specific procedure volumes for the 5-year period 2009-2013 from 
the German Federal Statistics Office for plain balloon angioplasty (PTA), DCB, BMS, 
DES, and atherectomy. In addition, surgical bypass and relevant amputation pro-
cedure volumes were collected. To assess general changes in hospitalization vol-
umes of patients with primary diagnosis of peripheral artery disease (PAD), we also 
obtained ICD-10-specific discharge information. We evaluated the 5-year growth for 
each of the studied treatment modalities, and analyzed their relative utilization 
level in the latest reported year, 2013. Results: Endovascular procedure volumes 
grew from 73,927 in 2009 to 98,730 in 2013 (+34%), while bypass surgery volumes 
decreased from 31,970 to 29,042 (-9%), for a combined growth of 21% in total pro-
cedure volumes. Hospitalizations with primary diagnosis of PAD increased by 11% 
in this period (168,845 to 187,563). At the same time, lower extremity amputations 
remained stable (+1.6%). However, a substantial shift from major to minor amputa-
tions could be observed (-14.5%; +10.5%). In 2013, PTA, DCB, BMS, DES, and atherec-
tomy constituted 51.6%, 16.3%, 28.0%, 0.9%, and 3.2% of the total endovascular case 
volume. DCBs exhibited the most rapid growth, with their relative share of endovas-
cular interventions increasing from 6.2% in 2009 to 16.3% in 2013. cOnclusiOns: 
Five-year national data from the German healthcare system demonstrate that the 
availability of new endovascular therapies has led to substantial growth in femo-
ropopliteal arterial disease procedure volumes, expanding the treated population 
and partially replacing surgical bypass treatment. Concurrently, our results suggest 
a trend towards improved limb salvage.
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Objectives: To provide on-line shared infrastructures among Payers and 
Companies, used by health personnel, regulatory bodies and Sponsors, in order 
to allow the management of medical devices delivery process, from prescription 
until direct reimbursement from National Health System. MethOds: Based on a 
long history in collecting and analyzing real-world data, CINECA Interuniversity 
Consortium has developed an innovative Cloud-based IT infrastructure for the 
entire management of the service arrangements among Pharmaceutical Companies 
and Payers. The solution is designed to ensure proper data collection aimed to 
evaluate appropriateness, assess device performance and estimate efficacy in a 
real-world context, according to highest quality and security industry standards. The 
system may foresee the direct distribution of device and materials to the patient, 
in order to speed up the process and increase compliance. Results: In innovative 
therapies setting, the web-based system has been used in Italy for more than 75.000 
patients with type 2 diabetes treated with antidiabetic drugs. Access to therapy was 
allowed through 3.741 diabetes specialists belonging to 1.278 dedicated centers. The 
system is being extended to manage and allow market access for innovative devices. 
The system can manage the entire process of device management (prescription, 
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Objectives: The use of medical images has become a great tool that enables a 
rapid diagnosis, aids in taking relevant decisions early in the process, facilitates 
the formulation of a second opinion in cases of doubt. Solid tumors are very rare in 
children and individual clinician experience is often quite limited. Yet the treatment 
decisions which must be made can be complex and diagnostic dilemmas are com-
mon. MethOds: Supported by a grant from EU-funded Project ENCCA (European 
Network for Cancer Research in Children and Adolescents), representatives from 
SIOPEL, GPOH, COG, and JPLT developed the Virtual Consultation System. VCS is a 
novel tool developed by Cineca Interuniversity Consortium to support clinical chal-
lenges in management of complex cases, which require the consultation among 
experts coming from different hospitals or countries. VCS allows to assess complex 
cases using relevant medical information from structured data (e-CRFs) and diag-
nostic DICOM images. VCS can be customized according to specific requirements 
in all of its components such as user roles, process flows, and the input and output 
information (i.e. e-CRFs, images, consensus form) linked to the different tasks in 
the review process. Results: The main output is a report containing the collec-
tive findings, conclusions and recommendations for the further treatment of the 
patient. The use of a web-based consultation system is an essential component 
of excellence in diseases care because it enables patients to have access to the 
best available global expertise. This tool is particular important for rare tumors 
where clinicians need to get consultation from other colleagues in different areas 
of the world. cOnclusiOns: This consultation service represents an opportunity 
to enhance the care of children with rare tumors and facilitates education of clini-
cians caring for such challenging patients. Such a consultation service may serve 
as a model for cooperative management of other rare malignancies.
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Objectives: A clinical pathway is defined as the succession of medical events 
that jointly aim at improving the patients’ condition. It provides efficient care by 
standardizing processes, reducing the variability of practices and improving the out-
comes. Hospital Information Systems contain valuable data about these pathways. 
However, they are hardly tapped due to their volume and complexity. The objective 
of the study is to factually describe the clinical pathways of patients implanted with 
a CRT defibrillator (CRT-D) on an 8 years timeline from the French PMSI database. 
The PMSI annually includes the records of all hospital stays in the country. This 
description will bring new knowledge about the patients care to find out the correla-
tions with their condition. MethOds: From the 2008 database in public hospitals, 
we extracted all hospital stays with an implantation of a CRT-D in France, leading to 
1,602 patients. The patient’s anonymous identifiers were used to find all their hos-
pital stays during the 2 previous years (2006-2008) and the 5 following years (2008-
2013), being a total of 16,931 stays. These data were analyzed using Process Mining 
methods to find similarities in the patient’s sequences of stays. We also developed 
a specific visualization tool to illustrate the results. Results: We quantified the 
hospitalization risks on a long-term follow-up: hospitalization for heart failure was 
observed 3 months prior to implantation in 51% of patients, and 8 months after 
implantation in 50%. 28% of patients were readmitted for the device’s replacement 
after 2 years and 2 months, and 20% died at the hospital within 5 years. These risks 
were also assessed depending on the patient’s comorbidities. cOnclusiOns: This 
study shows that Process Mining methods are relevant to analyze clinical pathways 
at a national scale from big sized database. This descriptive approach is the prereq-
uisite for predictive analytics.
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Objectives: Targeted therapies have a growing place within the therapeutic land-
scape and represent an innovative sector. Companion diagnostics (CD) are com-
plementary to targeted therapies; however there is an unbalanced environment 
between both technologies with limited incentive measures to support the develop-
ment of diagnostic tests. The aim of this analysis was to review and compare the 
existing processes in Europe and North America, and see how CD benefits could 
be rewarded. MethOds: An analysis was performed of the healthcare systems 
in France, the United Kingdom, Germany and the United-States. Advantages and 
disadvantages of country-specific pricing and reimbursement policies were high-
lighted. A literature review was then conducted to identify the benefits related to CD 
and potential processes to capture these benefits. Searches were run on electronic 
databases (i.e. MEDLINE and MEDLINE In-Process) and were supplemented by hand 
searches to ensure that most relevant publications were included. Results: The 
analysis of healthcare systems showed a lack of incentive measures to support the 
development and market access of CD. Benefits associated with CD can be grouped 
into two categories: the health benefits (e.g. prediction of the patient’s response) and 
the economic benefits (e.g. cost-saving due to decrease in the delay of response). To 
reward these benefits, several potential strategies were identified (e.g. intellectual 
property, reform of commissions) and the most reported one being the value-based 
pricing approach. cOnclusiOns: Value-based pricing approaches were widely 
reported to reward the benefits associated with CD. Moreover, a European Directive 
